Diabetes
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 – 95 percent of all cases. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, and basal insulin from our alliance partner Eli Lilly and Company, we are also focused on cardiometabolic indications with a high unmet medical need.
Latest Articles on Diabetes

GUARDIANS FOR HEALTH: Initiative for patients and physicians

The Adventures of Reggie the Red Blood Cell

The Future of Diabetes
Related Press Releases

Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
Links
Heart Talks
Heart Failure Matters
Downloads
Diabetic Retinopathy
Harold and Dorothy Patient Discussion Factsheet
Type 2 Diabetes
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (accessed Jan 2019)